These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28074489)

  • 1. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.
    Donovan JM; Zimmer M; Offman E; Grant T; Jirousek M
    J Clin Pharmacol; 2017 May; 57(5):627-639. PubMed ID: 28074489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.
    Finanger E; Vandenborne K; Finkel RS; Lee Sweeney H; Tennekoon G; Yum S; Mancini M; Bista P; Nichols A; Liu H; Fretzen A; Donovan JM
    J Neuromuscul Dis; 2019; 6(1):43-54. PubMed ID: 30452422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial.
    Finkel RS; Finanger E; Vandenborne K; Sweeney HL; Tennekoon G; Shieh PB; Willcocks R; Walter G; Rooney WD; Forbes SC; Triplett WT; Yum SW; Mancini M; MacDougall J; Fretzen A; Bista P; Nichols A; Donovan JM
    Neuromuscul Disord; 2021 May; 31(5):385-396. PubMed ID: 33678513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.
    Finkel RS; McDonald CM; Lee Sweeney H; Finanger E; Neil Knierbein E; Wagner KR; Mathews KD; Marks W; Statland J; Nance J; McMillan HJ; McCullagh G; Tian C; Ryan MM; O'Rourke D; Müller-Felber W; Tulinius M; Burnette WB; Nguyen CT; Vijayakumar K; Johannsen J; Phan HC; Eagle M; MacDougall J; Mancini M; Donovan JM;
    J Neuromuscul Dis; 2021; 8(5):769-784. PubMed ID: 34120912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying effects of orally bioavailable NF-
    Hammers DW; Sleeper MM; Forbes SC; Coker CC; Jirousek MR; Zimmer M; Walter GA; Sweeney HL
    JCI Insight; 2016 Dec; 1(21):e90341. PubMed ID: 28018975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deubiquitinating enzyme A20 negatively regulates NF-κB signaling in skeletal muscle in mdx mice.
    Charan RA; Hanson R; Clemens PR
    FASEB J; 2012 Feb; 26(2):587-95. PubMed ID: 22012122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.
    Acharyya S; Villalta SA; Bakkar N; Bupha-Intr T; Janssen PM; Carathers M; Li ZW; Beg AA; Ghosh S; Sahenk Z; Weinstein M; Gardner KL; Rafael-Fortney JA; Karin M; Tidball JG; Baldwin AS; Guttridge DC
    J Clin Invest; 2007 Apr; 117(4):889-901. PubMed ID: 17380205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent.
    Mancini M; Shafai G; Thaler E; Donovan JM; Finkel RS
    J Clin Pharm Ther; 2022 Jan; 47(1):33-37. PubMed ID: 34263472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy.
    Kumar A; Boriek AM
    FASEB J; 2003 Mar; 17(3):386-96. PubMed ID: 12631578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy.
    Monici MC; Aguennouz M; Mazzeo A; Messina C; Vita G
    Neurology; 2003 Mar; 60(6):993-7. PubMed ID: 12654966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV-based shRNA silencing of NF-κB ameliorates muscle pathologies in mdx mice.
    Yang Q; Tang Y; Imbrogno K; Lu A; Proto JD; Chen A; Guo F; Fu FH; Huard J; Wang B
    Gene Ther; 2012 Dec; 19(12):1196-204. PubMed ID: 22278411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy.
    Macaione V; Aguennouz M; Rodolico C; Mazzeo A; Patti A; Cannistraci E; Colantone L; Di Giorgio RM; De Luca G; Vita G
    Acta Neurol Scand; 2007 Feb; 115(2):115-21. PubMed ID: 17212615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age.
    Messina S; Vita GL; Aguennouz M; Sframeli M; Romeo S; Rodolico C; Vita G
    Acta Myol; 2011 Jun; 30(1):16-23. PubMed ID: 21842588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered ROS production, NF-κB activation and interleukin-6 gene expression induced by electrical stimulation in dystrophic mdx skeletal muscle cells.
    Henríquez-Olguín C; Altamirano F; Valladares D; López JR; Allen PD; Jaimovich E
    Biochim Biophys Acta; 2015 Jul; 1852(7):1410-9. PubMed ID: 25857619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy.
    Haslbeck KM; Friess U; Schleicher ED; Bierhaus A; Nawroth PP; Kirchner A; Pauli E; Neundörfer B; Heuss D
    Acta Neuropathol; 2005 Sep; 110(3):247-54. PubMed ID: 15986224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
    Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
    Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy.
    Chen YW; Nagaraju K; Bakay M; McIntyre O; Rawat R; Shi R; Hoffman EP
    Neurology; 2005 Sep; 65(6):826-34. PubMed ID: 16093456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-κB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model.
    Peterson JM; Wang DJ; Shettigar V; Roof SR; Canan BD; Bakkar N; Shintaku J; Gu JM; Little SC; Ratnam NM; Londhe P; Lu L; Gaw CE; Petrosino JM; Liyanarachchi S; Wang H; Janssen PML; Davis JP; Ziolo MT; Sharma SM; Guttridge DC
    Nat Commun; 2018 Aug; 9(1):3431. PubMed ID: 30143619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic ablation of P65 subunit of NF-κB in mdx mice to improve muscle physiological function.
    Yin X; Tang Y; Li J; Dzuricky AT; Pu C; Fu F; Wang B
    Muscle Nerve; 2017 Oct; 56(4):759-767. PubMed ID: 27997693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.